Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/5/2025 | $43.00 → $56.00 | Buy | BTIG Research |
7/10/2025 | $18.00 | Buy | Goldman |
10/24/2024 | $37.00 | Buy | UBS |
6/28/2024 | $37.00 | Buy | Jefferies |
1/31/2024 | $36.00 → $23.00 | Sector Outperform → Sector Perform | Scotiabank |
12/22/2023 | $45.00 | Buy | Mizuho |
10/25/2023 | $29.00 | Buy | BofA Securities |
10/11/2023 | $30.00 | Buy | Goldman |
BTIG Research reiterated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $56.00 from $43.00 previously
Goldman initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $18.00
UBS initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase up to 48,600 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About
– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by Syndax – – sNDA in R/R mNPM1 AML granted Priority Review; PDUFA action date of October 25, 2025 – – $517.9 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today repor
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, August 4, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, August 4, 2025. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Conference
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
144 - Syndax Pharmaceuticals Inc (0001395937) (Subject)
144 - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversa
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex
WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directo
– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by Syndax – – sNDA in R/R mNPM1 AML granted Priority Review; PDUFA action date of October 25, 2025 – – $517.9 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today repor
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, August 4, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, August 4, 2025. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Conference
– $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in mNPM1 and KMT2Ar AML – – $602.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, toda